A Comparative Study of Topical 20% Koh vs. Intralesional MMR Vaccine in Treatment of Molluscum Contagiosum

Background: Molluscum Contagiosum (MC) has no FDA-approved treatments as of yet. Although many other treatments have been suggested, the majority of the efcacy evidence comes from modest case studies. Objectives: The aim of the current work was to evaluate the safety as well as efcacy of intralesional MMR vaccine immunotherapy versus topical KOH (20 %) in the treatment of MC. A total of 100 patients (71females and 29 males) with multiple lesions of MC. Patients And Methods: They were divided into two equal groups at random; group 1 treated by MMR vaccine at 3weeks intervals with a maximum of 3 injections or clinical cure. Group 2 subjected to topical 20% KOH once daily for maximum ten weeks. Complete clinical response was attai Results: ned in 80% of MC patients who treated with MMR vaccine versus 86% of patients who treated with topical 20% KOH for 10 weeks, while 20 % of patients showed no response in group 1 versus 4% in group 2 after the end of therapy. without recurrence after 3 months in all patients demonstrating complete reaction. In group 1, most patients tolerated the side effects, which in 5% of cases manifested as erythema and hyperpigmentation. While in group 2, hypopigmentation (10%), hyperpigmentation (14%), pruritus (8%) during treatment were reported. There was signicant reported burning sensation among 25% of patients treated with topical potassium hydroxide (P = 0.047). It could be c Conclusion: oncluded that both topically applied KOH 20% and intralesional MMR vaccine are dependable, less expensive treatments for non-genital MC.